Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:AGN
CUSIP01849010
Phone862-261-7000
Debt
Debt-to-Equity Ratio0.36
Current Ratio1.10
Quick Ratio0.94
Price-To-Earnings
Trailing P/E Ratio10.61
Forward P/E Ratio10.80
P/E Growth1.24
Sales & Book Value
Annual Sales$15.94 billion
Price / Sales3.69
Cash Flow$39.6842 per share
Price / Cash4.37
Book Value$207.19 per share
Price / Book0.84
Profitability
EPS (Most Recent Fiscal Year)$16.35
Net Income$-4,125,500,000.00
Net Margins-11.94%
Return on Equity8.53%
Return on Assets5.00%
Miscellaneous
Employees17,800
Outstanding Shares339,060,000
Allergan (NYSE:AGN) Frequently Asked Questions
What is Allergan's stock symbol?
Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan pay dividends? What is the dividend yield for Allergan?
Allergan announced a quarterly dividend on Thursday, May 3rd. Investors of record on Friday, May 18th will be paid a dividend of $0.72 per share on Friday, June 15th. This represents a $2.88 annualized dividend and a yield of 1.66%. The ex-dividend date of this dividend is Thursday, May 17th. View Allergan's Dividend History.
How will Allergan's stock buyback program work?
Allergan announced that its board has initiated a share buyback plan on Tuesday, September 26th 2017, which authorizes the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's management believes its shares are undervalued.
How were Allergan's earnings last quarter?
Allergan plc (NYSE:AGN) posted its quarterly earnings results on Monday, April, 30th. The company reported $3.74 earnings per share for the quarter, beating the Zacks' consensus estimate of $3.36 by $0.38. The business earned $3.67 billion during the quarter, compared to the consensus estimate of $3.59 billion. Allergan had a positive return on equity of 8.53% and a negative net margin of 11.94%. Allergan's revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period last year, the business earned $3.35 earnings per share. View Allergan's Earnings History.
When is Allergan's next earnings date?
What guidance has Allergan issued on next quarter's earnings?
Allergan issued an update on its FY18 earnings guidance on Monday, April, 30th. The company provided earnings per share guidance of $15.65-16.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.66. The company issued revenue guidance of $15.15-15.35 billion, compared to the consensus revenue estimate of $15.24 billion.Allergan also updated its Q2 guidance to $4.00-4.20 EPS.
What price target have analysts set for AGN?
21 analysts have issued 12-month price targets for Allergan's shares. Their forecasts range from $160.07 to $265.00. On average, they expect Allergan's stock price to reach $211.2142 in the next year. View Analyst Ratings for Allergan.
What are Wall Street analysts saying about Allergan stock?
Here are some recent quotes from research analysts about Allergan stock:
- 1. Mizuho analysts commented, "We raise PT to $176 from $150 on stronger Botox expectations in both migraine and cosmetic indications, and view recent investor activism as positive to AGN." (6/8/2018)
- 2. Cantor Fitzgerald analysts commented, "This morning AGN reported a high quality 1Q18 EPS beat and raised its 2018 EPS guidance. This is clearly good news for the company, but we would note that a beat and raise was widely anticipated by the Street since AGN’s setup looked conservative heading into the year. Furthermore, if Restasis generics do not enter the market in 2018, we could see AGN continuing to beat its financial guidance throughout the year." (4/27/2018)
- 3. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing potential loss of exclusivity for many products in 2018 including Namenda XR and Restasis. In October 2017, a Texas federal district court invalidated four of the six patents covering Restasis, potentially opening doors for early generic competition. Though Restasis patents are scheduled to expire in August 2024, a generic version may be launched as early as mid-2018. Also, new competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares underperformed the industry in the past six months. " (1/2/2018)
Who are some of Allergan's key competitors?
Some companies that are related to Allergan include Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Sanofi (SNY), Bayer (BAYRY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Shire (SHPG) and Zoetis (ZTS).
Who are Allergan's key executives?
Allergan's management team includes the folowing people:
- Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 48)
- Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
- Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
- Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
- Mr. James C. D'Arecca, Chief Accounting Officer (Age 47)
Has Allergan been receiving favorable news coverage?
Press coverage about AGN stock has been trending somewhat negative recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Allergan earned a media sentiment score of -0.02 on Accern's scale. They also gave media headlines about the company an impact score of 46.70 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Allergan's major shareholders?
Allergan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.06%), Edgewood Management LLC (1.65%), Franklin Resources Inc. (1.59%), The Manufacturers Life Insurance Company (1.25%), Northern Trust Corp (1.21%) and Epoch Investment Partners Inc. (0.55%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.
Which institutional investors are selling Allergan stock?
AGN stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Prudential Financial Inc., Levin Capital Strategies L.P., Neuberger Berman Group LLC, BlackRock Inc., Epoch Investment Partners Inc., TCW Group Inc. and Swiss National Bank. View Insider Buying and Selling for Allergan.
Which institutional investors are buying Allergan stock?
AGN stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Edgewood Management LLC, Toronto Dominion Bank, Ceredex Value Advisors LLC, Point72 Asset Management L.P., Canyon Capital Advisors LLC, Canyon Capital Advisors LLC and Wells Fargo & Company MN. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.
How do I buy shares of Allergan?
Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan's stock price today?
One share of AGN stock can currently be purchased for approximately $173.42.
How big of a company is Allergan?
Allergan has a market capitalization of $59.40 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.
How can I contact Allergan?
Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]
MarketBeat Community Rating for Allergan (AGN)
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
